21亿脑卒中治疗药物争夺赛起:江苏联环药业等12家药企猛攻,先声药业重磅新药首仿资格花落谁家?

Ofweek维科网
Jan 06

2025年12月31日,据国家药监局药品审评中心(CDE)官网显示,江苏联环药业提交的4类仿制药“依达拉奉右莰醇注射用浓溶液”上市申请已获受理。这是继2025年11月14日上海凯宝新谊(新乡)药业申报失败后,该品种迎来的最新入局者。截图来源:CDE依达拉奉右莰醇注射用浓溶液是先声药业自主研发的1类创新药,于2020年7月30日获批上市,用于改善急性缺血性脑卒中所致的神经症状、日常生活活动能力和...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10